313 related articles for article (PubMed ID: 34461796)
1. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries.
Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
J Med Econ; 2021; 24(1):1098-1107. PubMed ID: 34461796
[TBL] [Abstract][Full Text] [Related]
2. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States.
Hu T; Weiss T; Owusu-Edusei K; Petigara T
J Med Econ; 2020 Dec; 23(12):1653-1660. PubMed ID: 33084447
[TBL] [Abstract][Full Text] [Related]
3. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong.
Mohanty S; Hu T; Yang G; Khan TK; Owusu-Edusei K; Sukarom I
Hum Vaccin Immunother; 2022 Nov; 18(5):2046433. PubMed ID: 35420975
[TBL] [Abstract][Full Text] [Related]
4. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
[TBL] [Abstract][Full Text] [Related]
5. Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA.
Owusu-Edusei K; Deb A; Johnson KD
Infect Dis Ther; 2022 Jun; 11(3):987-999. PubMed ID: 35084647
[TBL] [Abstract][Full Text] [Related]
6. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J
Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive value assessments for new pediatric pneumococcal conjugate vaccines.
Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
J Med Econ; 2021; 24(1):1083-1086. PubMed ID: 34433365
[TBL] [Abstract][Full Text] [Related]
8. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
Hu T; Song Y; Done N; Liu Q; Sarpong EM; Lemus-Wirtz E; Signorovitch J; Mohanty S; Weiss T
BMC Public Health; 2022 Sep; 22(1):1677. PubMed ID: 36064378
[TBL] [Abstract][Full Text] [Related]
9. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
12. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
13. Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children.
Ryman J; Weaver J; Yee KL; Sachs JR
Expert Rev Vaccines; 2022 Oct; 21(10):1515-1521. PubMed ID: 35997125
[TBL] [Abstract][Full Text] [Related]
14. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
15. Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs.
Horn M; Theilacker C; Sprenger R; von Eiff C; Mahar E; Schiffner-Rohe J; Pletz MW; van der Linden M; Scholz M
PLoS One; 2023; 18(2):e0281261. PubMed ID: 36791091
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of pediatric immunization program with 15-valent pneumococcal conjugate vaccine in Japan.
Tajima A; Abe M; Weaver J; Huang M
J Med Econ; 2023; 26(1):1034-1046. PubMed ID: 37555281
[TBL] [Abstract][Full Text] [Related]
18. Pneumococcal serotype evolution in Western Europe.
Tin Tin Htar M; Christopoulou D; Schmitt HJ
BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
[TBL] [Abstract][Full Text] [Related]
19. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
[TBL] [Abstract][Full Text] [Related]
20. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
